Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Pegylated interferon fractal pharmacokinetics: individualized dosing for hepatitis C virus infection.

Antimicrobial agents and chemotherapy - 1 Mar 2013

Jain Mamta K, Pasipanodya Jotam G, Alder Lara, Lee William M, Gumbo Tawanda

Abstract excerpt

Despite recent advances in hepatitis C virus (HCV) therapeutics, the combination of pegylated interferon and ribavirin (PEGIFN/RBV) remains the cornerstone of treatment. Optimization and individualization of PEGIFN dosing could improve outcomes. Week one PEGIFN serum concentrations in 42 HCV genotype 1-infected patients treated with conventional PEGIFN/RBV were analyzed using multicompartmental pharmacokinetic...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Area Under Curve
Share to Drug Administration Schedule

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Dosage Calculations

Share to Interferon-alpha

Share to Interferons

Share to Interleukins

Share to Polyethylene Glycols

Share to Ribavirin

Source

Open in PubMed Open full text

Identifiers

PMID: 23183434
DOI: 10.1128/AAC.02208-12
PMCID: PMC3591896

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Pegylated interferon fractal pharmacokinetics: individualized dosing for hepatitis C virus infection.PMID 23183434Read ↗

Customizing treatment to patient populations.Semantic proximity Read ↗

Derivation of Phase 3 dosing for peginterferon lambda-1a in chronic hepatitis C, Part 1: Modeling optimal treatment duration and sustained virologic response rates.Semantic proximity Read ↗

Scientific rationale and study design of the individualized dosing efficacy vs flat dosing to assess optimal pegylated interferon therapy (IDEAL) trial: determining optimal dosing in patients with genotype 1 chronic hepatitis C.Semantic proximity Read ↗

Viral kinetics in hepatitis C virus: special patient populations.Semantic proximity Read ↗

Feasibility of individualized treatment for hepatitis C patients in the real world.Semantic proximity Read ↗

A cost-effectiveness model to personalize antiviral therapy in naive patients with genotype 1 chronic hepatitis C.Semantic proximity Read ↗

Response rates to combination therapy for chronic HCV infection in a clinical setting and derivation of probability tables for individual patient management.Semantic proximity Read ↗

Derivation of Phase 3 dosing for peginterferon lambda-1a in chronic hepatitis C, Part 2: Exposure-response analyses for efficacy and safety variables.Semantic proximity Read ↗

Population pharmacokinetics and pharmacodynamics of ribavirin in patients with chronic hepatitis C genotype 1 infection.Semantic proximity Read ↗

Individualisation of antiviral therapy for chronic hepatitis C.Semantic proximity Read ↗

Pharmacodynamics of PEG-IFN-alpha-2a in HIV/HCV co-infected patients: implications for treatment outcomes.Semantic proximity Read ↗

Coevolution of the Hepatitis C Virus Polyprotein Sites in Patients on Combined Pegylated Interferon and Ribavirin TherapySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.